相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant
A. Hamasy et al.
LEUKEMIA (2017)
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Hsu-Ping Kuo et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Bardoxolone Methyl and a Related Triterpenoid Downregulate cMyc Expression in Leukemia Cells
Un-Ho Jin et al.
MOLECULAR PHARMACOLOGY (2017)
PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
Anella Yahiaoui et al.
PLOS ONE (2017)
Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment
Ailin Guo et al.
ONCOTARGET (2017)
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib
Varinder Kaur et al.
ANNALS OF HEMATOLOGY (2017)
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Ariela Noy et al.
BLOOD (2017)
Ibrutinib: A Review in Chronic Lymphocytic Leukaemia
Emma D. Deeks
DRUGS (2017)
The Bromodomain: A New Target in Emerging Epigenetic Medicine
Steven G. Smith et al.
ACS CHEMICAL BIOLOGY (2016)
Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia
Viralkumar Patel et al.
LEUKEMIA & LYMPHOMA (2016)
CD79B limits response of diffuse large B cell lymphoma to ibrutinib
Joo Hyun Kim et al.
LEUKEMIA & LYMPHOMA (2016)
Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism
Lianne E. Rotin et al.
ONCOTARGET (2016)
Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib
Ailin Guo et al.
ONCOTARGET (2016)
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations
Adam R. Johnson et al.
ACS CHEMICAL BIOLOGY (2016)
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas
E. Gaudio et al.
ANNALS OF ONCOLOGY (2016)
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma
Caron Jacobson et al.
BLOOD (2016)
Combination of duvelisib with either ibrutinib or dexamethasone prevents mTOR-dependent feedback in aggressive B-cell lymphoma cell lines
Kerry White et al.
CANCER RESEARCH (2016)
Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial
David E. Spaner et al.
HAEMATOLOGICA (2016)
Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers
Scott H. Watterson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Ibrutinib in chronic lymphocytic leukaemia: alone or in combination?
Tadeusz Robak
LANCET ONCOLOGY (2016)
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
Asher Chanan-Khan et al.
LANCET ONCOLOGY (2016)
Approaching resistance to ibrutinib in diffuse large B-cell lymphoma
Tabea Erdmann et al.
LEUKEMIA & LYMPHOMA (2016)
Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer
Chee-Seng Tan et al.
LUNG CANCER (2016)
NF-κB dysregulation in multiple myeloma
Geoffrey M. Matthews et al.
SEMINARS IN CANCER BIOLOGY (2016)
Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors
Claudia Neul et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3Kδ
Brahmam Pujala et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
Jan A. Burger et al.
NATURE COMMUNICATIONS (2016)
Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia
Rebecca Voltan et al.
ONCOTARGET (2016)
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
Shruti Sharma et al.
ONCOTARGET (2016)
Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial
David E. Spaner et al.
HAEMATOLOGICA (2016)
Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy
Martin F. M. de Rooij et al.
BLOOD (2015)
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation
Ta-Ming Liu et al.
BLOOD (2015)
The dual PI3K δ/γ inhibitor, RP6530, in combination with ibrutinib or fludarabine, synergistically enhances cytotoxicity in primary CLL cells in vitro.
Swaroop Vakkalanka et al.
CLINICAL CANCER RESEARCH (2015)
Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors
Sutapa Sinha et al.
CLINICAL CANCER RESEARCH (2015)
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
Fabiola Cervantes-Gomez et al.
CLINICAL CANCER RESEARCH (2015)
Ibrutinib: A Review of Its Use in Patients with Mantle Cell Lymphoma or Chronic Lymphocytic Leukaemia
Esther S. Kim et al.
DRUGS (2015)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
FDA-approved small-molecule kinase inhibitors
Peng Wu et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Kami J. Maddocks et al.
JAMA ONCOLOGY (2015)
Functional characterization of BTKC481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors
S. Cheng et al.
LEUKEMIA (2015)
25 Years of Small Molecular Weight Kinase Inhibitors: Potentials and Limitations
Doriano Fabbro
MOLECULAR PHARMACOLOGY (2015)
IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells
Shuai Dong et al.
BLOOD (2014)
Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells
Warren Fiskus et al.
MOLECULAR CANCER THERAPEUTICS (2014)
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
Junwei Shi et al.
MOLECULAR CELL (2014)
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
S. Cheng et al.
LEUKEMIA (2014)
The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients
J. Boysen et al.
LEUKEMIA (2014)
Targeting bromodomains: epigenetic readers of lysine acetylation
Panagis Filippakopoulos et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)
Natalia L. Komarova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Advances in kinase targeting: current clinical use and clinical trials
Mathias Rask-Andersen et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2014)
Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
David Chiron et al.
CANCER DISCOVERY (2014)
Targeting Bruton's tyrosine kinase in B cell malignancies
Rudi W. Hendriks et al.
NATURE REVIEWS CANCER (2014)
Ibrutinib and novel BTK inhibitors in clinical development
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies
Robert C. Rickert
NATURE REVIEWS IMMUNOLOGY (2013)
A Hypermorphic Missense Mutation in PLCG2, Encoding Phospholipase Cγ2, Causes a Dominantly Inherited Autoinflammatory Disease with Immunodeficiency
Qing Zhou et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2012)
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers
Komal Jhaveri et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2012)
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
Martin F. M. de Rooij et al.
BLOOD (2012)
Bruton's Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies
Yan Lou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Multi-Target Drugs: The Trend of Drug Research and Development
Jin-Jian Lu et al.
PLOS ONE (2012)
The Role of Bromodomain Proteins in Regulating Gene Expression
Gabrielle A. Josling et al.
GENES (2012)
BET domain co-regulators in obesity, inflammation and cancer
Anna C. Belkina et al.
NATURE REVIEWS CANCER (2012)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis
Julie A. Di Paolo et al.
NATURE CHEMICAL BIOLOGY (2011)
The resurgence of covalent drugs
Juswinder Singh et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Hsp90 and Co-Chaperones Twist the Functions of Diverse Client Proteins
Abbey Zuehlke et al.
BIOPOLYMERS (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Syk and pTyr'd: Signaling through the B cell antigen receptor
Robert L. Geahlen
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2009)
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
Yutaka Okawa et al.
BLOOD (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage
S. Giordano et al.
CURRENT MEDICINAL CHEMISTRY (2008)
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Jeffrey A. Engelman et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2008)
The Btk tyrosine kinase is a major target of the Bcr-Abi inhibitor dasatinib
Oliver Hantschel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Multi-target therapeutics: when the whole is greater than the sum of the parts
Grant R. Zimmermann et al.
DRUG DISCOVERY TODAY (2007)
Phosphoinositides in cell regulation and membrane dynamics
Gilbert Di Paolo et al.
NATURE (2006)
Treating imatinib-resistant leukemia: The next generation targeted therapies
Michael R. Burgess et al.
THESCIENTIFICWORLDJOURNAL (2006)
Strategies to overcome resistance to targeted protein kinase inhibitors
H Daub et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Cancer treatment with kinase inhibitors: what have we learnt from imatinib?
DM Ross et al.
BRITISH JOURNAL OF CANCER (2004)
PI3K and Btk differentially regulate B cell antigen receptor-mediated signal transduction
H Suzuki et al.
NATURE IMMUNOLOGY (2003)
Regulation of B-cell fate by antigen-receptor signals
H Niiro et al.
NATURE REVIEWS IMMUNOLOGY (2002)
分享论文
